|1.||Mori, Takashi: 4 articles (08/2006 - 06/2002)|
|2.||Asano, Takao: 4 articles (08/2006 - 06/2002)|
|3.||Tateishi, Narito: 4 articles (08/2006 - 06/2002)|
|4.||Shimoda, Taiji: 3 articles (05/2008 - 07/2004)|
|5.||Kato, Hiroyuki: 3 articles (05/2008 - 04/2003)|
|6.||Araki, Tsutomu: 3 articles (05/2008 - 04/2003)|
|7.||Funakoshi, Yosuke: 3 articles (04/2007 - 12/2006)|
|8.||Ishibashi, Hideyasu: 3 articles (04/2007 - 12/2006)|
|9.||Pettigrew, L Creed: 3 articles (04/2007 - 12/2006)|
|10.||Oki, Chie: 2 articles (05/2008 - 12/2004)|
|1.||Parkinson Disease (Parkinson's Disease)
05/01/2008 - "Thus, our present findings provide that the therapeutic strategies targeted to astrocytic modulation with arundic acid offers a great potential for restoring the functional capacity of the surviving dopaminergic neurons in individuals affected with Parkinson's disease."
04/15/2003 - "We examined the neuroprotective effects of a novel astrocyte-modulating agent, (R)-(-)-2-propyloctanoic acid (ONO-2506), in a mouse model of Parkinson's disease. "
05/01/2008 - "The authors investigated the protective effects of a novel astrocyte-modulating agent, arundic acid, in a 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP) mouse model of Parkinson's disease. "
12/24/2004 - "We examined the neuroprotective effects of a novel astrocyte-modulating agent, arundic acid (ONO-2506), in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. "
04/15/2003 - "Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease."
|2.||Neurologic Manifestations (Neurological Manifestations)
06/01/2002 - "The neurologic deficits were significantly improved, compared with the vehicle-treated groups, as early as 24 hours after the initial administration of ONO-2506. "
06/01/2005 - "The beneficial effects of arundic acid were most pronounced in 4/4-KI mice, wherein delayed infarct expansion together with deterioration of neurologic deficits was almost completely mitigated. "
06/01/2002 - "Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits."
06/01/2005 - "in 2/2-, 3/3-, or 4/4-KI mice in the vehicle groups: 16 +/- 2, 15 +/- 2, or 22 +/- 2; in the arundic acid groups: 11 +/- 2 (P < 0.001), 11 +/- 2 (P < 0.001), or 12 +/- 2 (P < 0.001), as compared with the vehicle groups), neurologic deficits, and S100/glial fibrillary acidic protein burden in the peri-infarct area. "
08/01/2006 - "Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice."
04/15/2003 - "The MPTP injection led to reactive astrocytosis in the striatum after 7 days, but ONO-2506 induced earlier, moderate astrocytic activation after 3-7 days. "
08/01/2006 - "Here, we report that beta-amyloid deposits along with amyloid-beta peptide/S100B levels, as well as beta-amyloid plaque-associated reactive gliosis (astrocytosis and microgliosis), were significantly ameliorated in arundic acid-treated Tg APP(sw) mice relative to vehicle-treated Tg APP(sw) mice at 19 months of age. "
|1.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|2.||S-100 calcium-binding protein beta subunit
|3.||Glutamic Acid (Glutamate)
|4.||Glial Fibrillary Acidic Protein
|6.||Amino Acid Transport System X-AG (Glutamate Transporter)
|8.||Valproic Acid (Valproate, Semisodium)